NeuroSense Therapeutics (NASDAQ:NRSN) Posts Earnings Results

NeuroSense Therapeutics (NASDAQ:NRSN) issued its earnings results on Wednesday. The company reported ($0.11) earnings per share for the quarter, Zacks reports.

NeuroSense Therapeutics Stock Up 3.7 %

NRSN traded up $0.04 on Wednesday, reaching $1.13. The company had a trading volume of 409,189 shares, compared to its average volume of 264,800. NeuroSense Therapeutics has a 1 year low of $0.51 and a 1 year high of $2.33. The stock has a market capitalization of $15.45 million, a PE ratio of -1.32 and a beta of 1.38. The stock has a 50-day moving average price of $1.12 and a 200-day moving average price of $1.03.

Wall Street Analyst Weigh In

Separately, Maxim Group reiterated a “hold” rating on shares of NeuroSense Therapeutics in a research note on Monday.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.